BEIGF:OTCMKTS
BeOne Medicines
USD 21,95
0,00%
(0,00) 1D
9 Jun., 12:49:46 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
45,54 mjd
Avg. vol.
0,00
Volume
0,00
52-wk high
USD 24,92
52-wk low
USD 21,95
Beta
0,86
Shares outstanding
1,43 mjd
No. of employees
12 k
Mkt. cap
45,54 mjd
Avg. vol.
0,00
Volume
0,00
52-wk high
USD 24,92
52-wk low
USD 21,95
Beta
0,86
Shares outstanding
1,43 mjd
No. of employees
12 k
News stories
From web sources and news partners
MarketBeat
·
13 uur gelede
BeOne Medicines (NASDAQ:ONC) Stock: Insider Chan Henry Lee Sells 1,115 Shares
Investor's Business Daily
·
1 dag gelede
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
TipRanks
·
4 dae gelede
BeOne Medicines Advances Sonrotoclax Safety Study in Patients With Severe Liver Impairment
TipRanks
·
4 dae gelede
BeOne Medicines Advances Tacabrutideg With New Liver Function Study
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 k
Founded28 Okt. 2010
Headquarters-
Sector-
Websitebeonemedicines.com